Richard D. Mamelok

4.8k total citations
55 papers, 3.6k citations indexed

About

Richard D. Mamelok is a scholar working on Transplantation, Oncology and Surgery. According to data from OpenAlex, Richard D. Mamelok has authored 55 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Transplantation, 14 papers in Oncology and 11 papers in Surgery. Recurrent topics in Richard D. Mamelok's work include Renal Transplantation Outcomes and Treatments (20 papers), Pharmacological Effects and Toxicity Studies (7 papers) and Transplantation: Methods and Outcomes (6 papers). Richard D. Mamelok is often cited by papers focused on Renal Transplantation Outcomes and Treatments (20 papers), Pharmacological Effects and Toxicity Studies (7 papers) and Transplantation: Methods and Outcomes (6 papers). Richard D. Mamelok collaborates with scholars based in United States, Germany and Netherlands. Richard D. Mamelok's co-authors include Teun van Gelder, Donald W. Northfelt, Dirk Kuypers, Charles Du Mond, Bruce J. Dezube, James Thommes, Yannick Le Meur, Lawrence D. Kaplan, Margaret A. Fischl and Howard J. Eisen and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Nature Biotechnology.

In The Last Decade

Richard D. Mamelok

53 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard D. Mamelok United States	30	1.6k	953	846	654	537	55	3.6k
Kenneth L. Brayman United States	38	2.1k 1.3×	2.5k 2.7×	267 0.3×	723 1.1×	401 0.7×	174	5.1k
Joan Torrás Spain	38	1.7k 1.0×	1.5k 1.6×	455 0.5×	1.1k 1.7×	252 0.5×	214	5.2k
Scott A. Gruber United States	33	1.5k 0.9×	1.2k 1.2×	443 0.5×	529 0.8×	211 0.4×	108	3.2k
Kota Takahashi Japan	35	1.3k 0.8×	1.5k 1.6×	483 0.6×	452 0.7×	138 0.3×	199	4.3k
J. Michael Millis United States	45	1.0k 0.6×	3.8k 4.0×	767 0.9×	1.4k 2.1×	270 0.5×	172	6.0k
Roy Calne United Kingdom	36	2.1k 1.3×	3.5k 3.6×	474 0.6×	1.2k 1.8×	110 0.2×	119	5.9k
Oriol Bestard Spain	32	2.1k 1.3×	1.2k 1.3×	387 0.5×	871 1.3×	278 0.5×	159	3.6k
Ashok Jain United States	29	1.8k 1.1×	1.8k 1.9×	431 0.5×	683 1.0×	249 0.5×	51	3.9k
Felix Braun Germany	25	851 0.5×	770 0.8×	265 0.3×	494 0.8×	226 0.4×	156	2.5k
Thomas R. Hakala United States	30	1.2k 0.8×	1.5k 1.6×	396 0.5×	419 0.6×	89 0.2×	78	3.2k

Countries citing papers authored by Richard D. Mamelok

Since Specialization

Citations

This map shows the geographic impact of Richard D. Mamelok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard D. Mamelok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard D. Mamelok more than expected).

Fields of papers citing papers by Richard D. Mamelok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard D. Mamelok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard D. Mamelok. The network helps show where Richard D. Mamelok may publish in the future.

Co-authorship network of co-authors of Richard D. Mamelok

This figure shows the co-authorship network connecting the top 25 collaborators of Richard D. Mamelok. A scholar is included among the top collaborators of Richard D. Mamelok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard D. Mamelok. Richard D. Mamelok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pariser, David M., et al.. (2021). 26301 Pharmacokinetic analyses show limited systemic exposure with topical glycopyrronium tosylate. Journal of the American Academy of Dermatology. 85(3). AB96–AB96. 1 indexed citations

Pariser, David M., Edward Lain, Richard D. Mamelok, Janice Drew, & Diane R. Mould. (2021). Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis. Clinical Pharmacokinetics. 60(5). 665–676. 7 indexed citations

Glaser, Dee Anna, Adelaide A. Hebert, Alexander Nast, et al.. (2019). A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis. American Journal of Clinical Dermatology. 20(4). 593–604. 21 indexed citations

Glaser, Dee Anna, Adelaide A. Hebert, Alexander Nast, et al.. (2018). Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Journal of the American Academy of Dermatology. 80(1). 128–138.e2. 46 indexed citations

Burdick, Michael D., et al.. (2016). Comparison of the Pharmacokinetics of Ketorolac Tromethamine After Continuous Subcutaneous Infusion and Repeat Intramuscular Bolus Injections in Healthy Adult Subjects. Clinical Pharmacology in Drug Development. 6(4). 343–349. 4 indexed citations

Gelder, Teun van, Hélio Tedesco‐Silva, Johan W. de Fijter, et al.. (2011). How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation. Therapeutic Drug Monitoring. 33(2). 155–164. 12 indexed citations

Gelder, Teun van, Hélio Tedesco‐Silva, Johan W. de Fijter, et al.. (2010). Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid. Transplantation. 89(5). 595–599. 45 indexed citations

Schaik, Ron H. N. van, Madelon van Agteren, Johan W. de Fijter, et al.. (2009). UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients. Clinical Pharmacology & Therapeutics. 86(3). 319–327. 97 indexed citations

Nashan, Björn, Faouzi Saliba, François Durand, et al.. (2009). Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transplantation. 15(2). 136–147. 32 indexed citations

10.

Hesselink, Dennis A., Ron H. N. van Schaik, Madelon van Agteren, et al.. (2008). CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenetics and Genomics. 18(4). 339–348. 102 indexed citations

11.

McNeil, Keith, Allan R. Glanville, Thorsten Wahlers, et al.. (2006). Comparison of Mycophenolate Mofetil and Azathioprine for Prevention of Bronchiolitis Obliterans Syndrome in De Novo Lung Transplant Recipients. Transplantation. 81(7). 998–1003. 88 indexed citations

12.

Gelder, Teun van, Yannick Le Meur, Leslie M. Shaw, et al.. (2006). Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation. Therapeutic Drug Monitoring. 28(2). 145–154. 258 indexed citations

13.

Mamelok, Richard D.. (2005). From Mechanisms to Long-Term Benefits. Transplantation. 79(Supplement). S43–S44. 14 indexed citations

14.

Amantea, Michael, Raleigh A. Bowden, Alan Forrest, et al.. (1999). The Population Pharmacokinetics of Amphotericin B Colloidal Dispersion in Patients Receiving Bone Marrow Transplants. Chemotherapy. 45(Suppl. 1). 48–53. 7 indexed citations

15.

Northfelt, Donald W., Bruce J. Dezube, James Thommes, et al.. (1998). Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.. Journal of Clinical Oncology. 16(7). 2445–2451. 485 indexed citations

16.

Kobashigawa, Jon, L.W. Miller, Dale G. Renlund, et al.. (1998). A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1. Transplantation. 66(4). 507–515. 440 indexed citations

17.

White, Mary H., E. Anaissie, Shimon Kusne, et al.. (1997). Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.. PubMed. 24(4). 635–42. 133 indexed citations

18.

Amantea, Michael, Alan Forrest, Donald W. Northfelt, & Richard D. Mamelok. (1997). Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clinical Pharmacology & Therapeutics. 61(3). 301–311. 83 indexed citations

19.

Mamelok, Richard D., et al.. (1988). Organic Anion Transport by Basal-Lateral Membranes: Effect of PAH and Furosemide on Each Other’s Transport. Pharmacology. 37(4). 268–276. 3 indexed citations

20.

Edmonds, Brian T., et al.. (1985). Alloxan stimulates p-aminohippurate uptake in renal basal-lateral membranous vesicles. Biochimica et Biophysica Acta (BBA) - Biomembranes. 814(2). 333–340. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact